Question 1

What is Opioid-Induced Constipation?

Accepted Answer

Opioid-induced Constipation (OIC) is defined as a change from baseline in bowel habits after initiation of opioids that includes any of the following symptoms: reduced bowel movement frequency, development or worsening of straining to pass stool, a sense of incomplete rectal evacuation, and harder stool consistency.

Question 2

Who are the leading Opioid-Induced Constipation Companies?

Accepted Answer

Leading Opioid Induced Constipation Companies in the market include HealthCore Inc, Forest Laboratories, Ironwood Pharamceuticals Inc, Progenics Pharmaceuticals Inc, AstraZeneca, Nektar Therapeutics, Apices Soluciones SL, Shionogi Inc, Mundipharma Research GmbH & Co KG, QuintilesIMS Inc, Alkermes Inc, Theravance Biopharma, Cubist Pharmaceuticals LLC, Pfizer, BioGaia Pharma AB, Valinor Pharma LLC, Takeda, and others.

Question 3

What are the key strengths of Opioid-Induced Constipation Market Report?

Accepted Answer

Key strengths of Opioid-Induced Constipation Market Report are 10 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Opioid-Induced Constipation Market Size, Drug Uptake, Pipeline Therapies, Opioid-Induced Constipation Market Drivers and Market Barriers.

Question 4

Which country is expected to account for the most significant prevalent cases for Opioid-Induced Constipation in the 7MM?

Accepted Answer

The United States is expected to account for the highest Opioid-Induced Constipation Prevalent Cases.